Research programme: anticancer therapeutics - Institute for Cancer Prevention/Integrated BioPharma

Drug Profile

Research programme: anticancer therapeutics - Institute for Cancer Prevention/Integrated BioPharma

Latest Information Update: 21 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institute for Cancer Prevention; Integrated BioPharma
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 06 Dec 2005 INB:Biotechnologies and City of Hope Cancer Center have entered into an agreement to conduct a phase I trial with Phytosel®
  • 12 Jan 2004 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top